Drug Trial Radar · NCT03168139
Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Jul 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Apr 18, 2017
Primary completion
Mar 25, 2020
Study completion Mar 25, 2020
Sponsor
- Lead sponsor
- TME Pharma AGIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- May 30, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to show that the type, number and/or distribution of tumor metastases infiltrating immune cells such as cytotoxic T cells and/or the cytokine signature in the tumor metastases can be modulated by treatment with olaptesed pegol and to explore safety, tolerability and efficacy of olaptesed pegol in combination with pembrolizumab as a basis for subsequent studies in combination with immunotherapies, in particular checkpoint inhibitors.
Conditions
- Metastatic Colorectal Cancer
- Metastatic Pancreatic Cancer
Interventions
Olaptesed pegol - MonotherapyDrug
Monotherapy (MT) period: Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks
Olaptesed pegol + Pembrolizumab - Combination TherapyDrug
Combination therapy (CT) period: Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total
Primary outcomes
What the sponsor says the trial is designed to measure.
- Monotherapy: PharmacodynamicsTime frame: up to 14 days
- Combination Therapy: Safety - adverse events, vital signs, ECG, hematology & safety laboratoryTime frame: up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
Heidelberg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.